

**Celadon Pharmaceuticals Plc**  
**("Celadon", the "Group" or the "Company")**

**Funding Update**

**London, 30 May 2025** - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, provides an update on its financial position. The Company announced on 30 April 2025 that it had sufficient funding to trade into May 2025 as it sought to secure additional funding for the business.

The Company has been unable to obtain funding under its existing credit facility and the directors no longer expect to receive funds under this facility in the near future. The Company has however, over recent weeks, been engaged with a new finance provider who has concluded due diligence and who has indicated he is in the process of making funds available.

As of today the Company has limited working capital and its ability to continue to trade is fully dependent upon receiving funds from the new finance provider, continued creditor and stakeholder support. In the event the Company cannot secure funds over the coming days, the directors will have to protect the interests of all stakeholders and the Company will be placed into administration.

In the event funding for the Group is secured, the Company remains committed to proceeding with a cancellation of trading of the Company's ordinary shares on AIM.

A further announcement will be made as and when appropriate.

**Enquiries:**

**Celadon Pharmaceuticals Plc**  
James Short

Via Canaccord Genuity Limited

**Canaccord Genuity Limited (Nominated Adviser and Broker)**  
Bobbie Hilliam / Andrew Potts

+44 (0)20 7523 8000

**Global Investment Strategy UK Limited (Joint Broker)**  
James Sheehan

+44 (0)20 7048 9400

**About Celadon Pharmaceuticals Plc**

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website [www.celadonpharma.com](http://www.celadonpharma.com)

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDFLFIDESIIVIE